Daily Realities: Managing Symptoms and Knowing the Warning Signs
At a Glance
In progressive-relapsing MS, symptoms may worsen gradually, while heat, fever, or infection can temporarily intensify existing problems without new damage. Rehabilitation, targeted medicines, and knowing emergency warning signs help support daily function and prompt safe medical care.
Living with progressive MS means managing a shifting set of physical and cognitive challenges. Because symptoms often change slowly, it can be easy to overlook the cumulative impact they have on your daily life. However, focusing on symptom management—not just the disease itself—can significantly improve your quality of life [1][2].
Managing Daily Symptoms
The burden of progressive MS is often “multidomain,” meaning it affects many systems at once [1]. Working with a multidisciplinary team (neurologists, physical therapists, occupational therapists, and speech-language pathologists) is the standard for addressing these issues [3][2].
- Mobility and Walking: Walking difficulties and balance problems are common [4].
- Management: Physical Therapy (PT) is a cornerstone of supportive treatment, focusing on strength, balance, and safe mobility [1]. Options include outpatient exercise programs and assistive devices [5].
- Medication: Dalfampridine (Ampyra) may improve walking speed for some. However, it is absolutely contraindicated (must not be used) in anyone with a history of seizures or moderate-to-severe kidney disease [6].
- Spasticity: This is a feeling of stiffness or muscle spasms that can make movement difficult [1].
- Management: Stretching, positioning, and exercise are first-line defenses [5].
- Medication: Oral medications like baclofen can help, but they may cause side effects like drowsiness or increased weakness [7]. For stiffness limited to a specific area (focal spasticity), botulinum toxin injections may be used to relax those specific muscles [8].
- Fatigue and Cognition: These are often the most under-treated symptoms [1].
- Bladder and Bowel Function: These issues often intensify over time [4][11].
Relapses vs. Pseudo-Exacerbations
A true relapse is generally a new or significantly worsening neurological symptom that lasts at least 24 hours in the absence of a fever or infection.
In progressive MS, you may also experience a pseudo-exacerbation. This is a temporary worsening of your existing MS symptoms caused by an external trigger—most commonly a fever, an infection (like a UTI), or overexposure to heat [12]. Unlike a true relapse, a pseudo-exacerbation does not involve new damage to the brain or spine; symptoms usually return to your “baseline” once the trigger is removed [12]. Do not attempt to diagnose a relapse yourself; contact your MS care team for a clinical assessment.
Urgent Warnings and Emergency Care
While most MS changes are slow, certain “red flag” symptoms require immediate medical evaluation. It is critical to know when to call your neurologist versus when to call emergency services (911).
1. Medical Emergencies (Call 911 / Go to the ER)
Do not assume every sudden worsening is a pseudo-exacerbation. Some symptoms may indicate a stroke, severe infection (sepsis), or another life-threatening event:
- Stroke Symptoms: Sudden one-sided weakness, facial droop, sudden difficulty speaking or understanding speech, or sudden vision loss [13].
- Severe Breathing or Swallowing Issues: Sudden difficulty breathing, severe choking during meals, or severe swelling (which could indicate a dangerous allergic reaction to an infusion) [14][15].
- Seizures: Any first-time seizure, or a seizure lasting longer than a few minutes [6].
- Signs of Sepsis/Severe Infection: High fever with chills, rapid heart rate, very low blood pressure, or profound, sudden unresponsiveness [7][13].
2. Urgent Neurological Care (Contact Your Specialist Quickly)
If you are on disease-modifying therapies (DMTs) that suppress the immune system (such as ocrelizumab or fingolimod), your body may not fight off infections normally [16][17].
- Atypical Infections: Sudden, severe confusion, major increases in weakness, or frequent new falls might indicate an infection like a Urinary Tract Infection (UTI), but they can also indicate medication toxicity or other urgent problems. These require prompt clinical assessment [18][12].
- Progressive Multifocal Leukoencephalopathy (PML): PML is a rare but very serious brain infection that can occur with certain MS medications [19][17]. Watch for any new and steadily worsening neurological problem that develops subacutely (over days or weeks), such as worsening vision loss, clumsiness, or major changes in personality or thinking [19][16].
Common questions in this guide
How can I tell a true MS relapse from a temporary pseudo-exacerbation?
What progressive MS symptoms mean I should call 911?
Can dalfampridine help walking problems in progressive MS?
What treatments can help spasticity in progressive MS?
Can MS medications increase the risk of infection or PML?
How are fatigue, thinking changes, and bladder problems managed in progressive MS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which of my symptoms are likely from MS 'activity' versus long-term 'progression'?
- 2.Is my current walking speed or balance at a point where a trial of dalfampridine (Ampyra) is appropriate, given my kidney function?
- 3.What is our specific action plan for distinguishing a true MS relapse from an infection or heat-related 'pseudo-exacerbation'?
- 4.Can you recommend a physical therapist who specializes in neuro-rehabilitation for progressive MS?
- 5.What specific warning signs should prompt me to go to the emergency room instead of calling your office?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (19)
- 1
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study.
Schreiber H, Penner IK, Maier T, et al.
Journal of central nervous system disease 2024; (16()):11795735241296001 doi:10.1177/11795735241296001.
PMID: 39449826 - 2
Progressive Multiple Sclerosis.
Willis MA, Fox RJ
Continuum (Minneapolis, Minn.) 2016; (22(3)):785-98 doi:10.1212/CON.0000000000000323.
PMID: 27261682 - 3
Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal.
Thompson AJ, Carroll W, Ciccarelli O, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2022; (28(1)):16-28 doi:10.1177/13524585211059766.
PMID: 34850641 - 4
Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.
Zhang Y, Taylor BV, Simpson S, et al.
European journal of neurology 2019; (26(1)):155-161 doi:10.1111/ene.13786.
PMID: 30133059 - 5
Effectiveness of Physiotherapy Interventions on Spasticity in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Etoom M, Khraiwesh Y, Lena F, et al.
American journal of physical medicine & rehabilitation 2018; (97(11)):793-807 doi:10.1097/PHM.0000000000000970.
PMID: 29794531 - 6
Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis.
Vaheb S, Farzan M, Afshari-Safavi A, et al.
International journal of preventive medicine 2025; (16()):6 doi:10.4103/ijpvm.ijpvm_292_23.
PMID: 40046692 - 7
Acute Encephalopathy in Multiple Sclerosis With Renal Failure: Synergistic Neurotoxicity of Baclofen and Meropenem.
D B, M R, G C, et al.
Case reports in infectious diseases 2026; (2026()):7420497 doi:10.1155/crdi/7420497.
PMID: 42327926 - 8
Synergic use of botulinum toxin injection and radial extracorporeal shockwave therapy in Multiple Sclerosis spasticity.
Marinaro C, Costantino C, D'Esposito O, et al.
Acta bio-medica : Atenei Parmensis 2021; (92(1)):e2021076 doi:10.23750/abm.v92i1.11101.
PMID: 33682833 - 9
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study.
Oreja-Guevara C, Meca-Lallana JE, Díaz-Díaz J, et al.
Multiple sclerosis and related disorders 2024; (90()):105787 doi:10.1016/j.msard.2024.105787.
PMID: 39142050 - 10
Cognitive function in primary and secondary progressive multiple sclerosis: A multiparametric magnetic resonance imaging study.
Mistri D, Cacciaguerra L, Valsasina P, et al.
European journal of neurology 2023; (30(9)):2801-2810 doi:10.1111/ene.15900.
PMID: 37246467 - 11
Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.
Rajabi M, Shafaeibajestan S, Asadpour S, et al.
Neuropsychopharmacology reports 2025; (45(3)):e70039 doi:10.1002/npr2.70039.
PMID: 40653594 - 12
Urinary tract infection in patients with multiple sclerosis: An overview.
Medeiros Junior WLG, Demore CC, Mazaro LP, et al.
Multiple sclerosis and related disorders 2020; (46()):102462 doi:10.1016/j.msard.2020.102462.
PMID: 32890816 - 13
Multiple Sclerosis: An Emergency Medicine-Focused Narrative Review.
Pelletier J, Sugar D, Koyfman A, Long B
The Journal of emergency medicine 2024; (66(4)):e441-e456 doi:10.1016/j.jemermed.2023.12.003.
PMID: 38472027 - 14
Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report.
Rauniyar R, Rauniyar R, Agrawal A, et al.
Clinical case reports 2022; (10(1)):e05299 doi:10.1002/ccr3.5299.
PMID: 35079395 - 15
Depressive Symptoms and Suicidal Ideation in Progressive Multiple Sclerosis Compared With Relapsing-Remitting Multiple Sclerosis: Results From a Cross-sectional Survey.
Knowles LM, Esselman EC, Turner AP, et al.
Archives of physical medicine and rehabilitation 2021; (102(4)):694-701 doi:10.1016/j.apmr.2020.09.385.
PMID: 33080210 - 16
Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S, Hoshi MM, Pul R, et al.
Clinical neurology and neurosurgery 2020; (197()):106142 doi:10.1016/j.clineuro.2020.106142.
PMID: 32920498 - 17
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
Faissner S, Gold R
CNS drugs 2018; (32(3)):269-287 doi:10.1007/s40263-018-0488-6.
PMID: 29600441 - 18
Retrospective Cohort Study of Patient-Reported Urinary Tract Infection Signs and Symptoms Among Individuals With Neurogenic Bladder.
Wirth M, Suda KJ, Burns SP, et al.
American journal of physical medicine & rehabilitation 2023; (102(8)):663-669 doi:10.1097/PHM.0000000000002204.
PMID: 36927768 - 19
Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Wolf AB, Corboy JR
Neurology. Clinical practice 2024; (14(5)):e200330 doi:10.1212/CPJ.0000000000200330.
PMID: 38919933
This page is for informational purposes only and does not constitute medical advice. It explains symptom management and warning signs in progressive MS; contact your MS care team or emergency services for urgent symptoms.
Get notified when new evidence is published on progressive relapsing multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.